Form 4: Aadi Bioscience Director Acquires Stock Options

Aadi Bioscience director, Zhao Baiteng, acquired 61,192 stock options on December 19, 2024, which vest over three years.

Summary

• Director Zhao Baiteng of Aadi Bioscience acquired 61,192 stock options on December 19, 2024.
• The options have an exercise price of $2.32.
• The options vest monthly over three years, starting from the grant date.
• The options will be fully vested and exercisable by December 19, 2027, assuming continued service.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of stock option grants to a director, which is generally viewed positively as it aligns interests. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Risks

• The vesting of the options is contingent on the director's continued service with the company.

Future Outlook

The stock options will vest over the next three years, contingent on the director's continued service.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing directors and aligning their interests with shareholders in the biotechnology industry.
• The vesting schedule of three years is also a common practice to ensure long-term commitment from the director.

Stakeholder Impact

• The stock option grant may positively impact shareholder sentiment by aligning the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, insider trading, Aadi Bioscience, Zhao Baiteng, equity incentive plan, director